← 產業報告目錄
India Sickle Cell Anaemia Market Research Report Forecast to 2032
授權報價
| Single User Price | $2,950 USD |
| Multi User Licence (up to 10 users) | $3,950 USD |
| Enterprisewide Price (Global Site License) | $5,250 USD |
報告摘要
India Sickle Cell Anaemia Market Research Report Forecast to 2032
Market Overview
India Sickle Cell Anaemia Market is anticipated to register a healthy CAGR of 12.50% during the review period.
Sickle cell anemia is a genetic blood disorder characterized by the presence of abnormal hemoglobin that causes red blood cells to become rigid and sickle shaped. It happens due to a mutation on the sixth position of the beta chain of hemoglobin where glutamic acid amino acid gets converted into valine. The treatment procedure includes blood transfusions, medication, and bone marrow transplants.
The increased prevalence of sickle cell disease in India increases the demand for drug treatment, and growing government support and policies associated with sickle cell anemia in India are major factors driving the growth of the India sickle cell anemia market. However, the high cost of bone marrow transplants and the side effects associated with drug treatment are expected to restrain the growth of the Indian market. Nevertheless, the Indian government is forming partnerships with Indian manufacturers to produce affordable sickle cell disease medications, which is attributed to creating lucrative opportunities for the players operating in the Indian market.
Market Segmentation
Based on type, the India sickle cell anemia market has been segmented into sickle cell anemia, sickle hemoglobin-c disease (SC), sickle beta-plus thalassemia, and sickle beta-zero thalassemia.
Based on diagnosis &treatment, the market has been segmented into diagnosis, and treatment.
Major Players
The key market competitors are Cipla Inc, Novartis AG, United Biotech Pvt ltd., Pfizer Inc, Emmaus Medical, Inc, Neon, Celon Labs, and Teva Pharmaceutical Industries Ltd.
目錄 Table of Contents
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 13
2 MARKET INTRODUCTION 15
2.1 DEFINITION 15
2.2 SCOPE OF THE STUDY 15
2.3 RESEARCH OBJECTIVE 15
2.4 MARKET STRUCTURE 16
3 RESEARCH METHODOLOGY 17
3.1 OVERVIEW 17
3.2 DATA FLOW 19
3.2.1 Data Mining Process 19
3.3 PURCHASED DATABASE: 20
3.4 SECONDARY SOURCES: 21
3.4.1 Secondary Research data flow: 22
3.5 PRIMARY RESEARCH: 23
3.5.1 Primary Research DATA FLOW: 24
3.5.2 Primary Research: Number of Interviews conducted 25
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: 25
3.6.1 Revenue Analysis Approach 25
3.7 DATA FORECASTING 26
3.7.1 Data forecasting Technique 26
3.8 DATA MODELLING 27
3.8.1 microeconomic factor analysis: 27
3.8.2 Data MODELLING: 28
3.9 TEAMS AND ANALYST CONTRIBUTION 30
4 MARKET DYNAMICS 32
4.1 INTRODUCTION 32
4.2 DRIVERS 33
4.2.1 Growing Government Support and Policies associated with sickle cell anaemia in India 33
4.2.2 Increased prevalence of Sickle CELL among india Increases the demand for drug treatment 34
4.3 RESTRAINTS 35
4.3.1 High cost of bone marrow transplant and side effects associated with drug treatment 35
4.4 OPPORTUNITY 36
4.4.1 Indian government is forming partnerships with Indian manufacturers to produce affordable sickle cell disease medications 36
5 MARKET FACTOR ANALYSIS 37
5.1 PORTER'S FIVE FORCES MODEL 37
5.1.1 Threat of New Entrants 37
5.1.2 BARGAINING POWER OF SUPPLIERS 38
5.1.3 Threat of Substitutes 38
5.1.4 Bargaining Power of Buyers 38
5.1.5 Intensity of Rivalry 38
5.2 IMPACT OF COVID-19 ON THE INDIA SICKLE CELL ANAEMIA MARKET 39
6 INDIA SICKLE CELL ANAEMIA MARKET, BY TYPE 41
6.1 OVERVIEW 41
7 INDIA SICKLE CELL ANAEMIA MARKET, BY DIAGNOSIS &TREATMENT 44
7.1 OVERVIEW 44
8 COMPETITIVE LANDSCAPE 49
8.1 INTRODUCTION 49
8.2 MARKET SHARE ANALYSIS, 2022 49
8.3 COMPETITOR DASHBOARD 50
8.4 PUBLIC PLAYERS STOCK SUMMARY 51
8.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 51
8.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 52
8.6.1 product approval 52
9 COMPANY PROFILES 53
9.1 CIPLA LTD 53
9.1.1 COMPANY OVERVIEW 53
9.1.2 FINANCIAL OVERVIEW 54
9.1.3 PRODUCTS OFFERED 54
9.1.4 KEY DEVELOPMENTS 54
9.1.5 SWOT ANALYSIS 55
9.1.6 KEY STRATEGIES 55
9.2 UNITED BIOTECH PVT LTD. 56
9.2.1 COMPANY OVERVIEW 56
9.2.2 FINANCIAL OVERVIEW 56
9.2.3 PRODUCTS OFFERED 56
9.2.4 KEY DEVELOPMENTS 56
9.2.5 KEY STRATEGIES 57
9.3 NEON 58
9.3.1 COMPANY OVERVIEW 58
9.3.2 FINANCIAL OVERVIEW 58
9.3.3 PRODUCTS OFFERED 58
9.3.4 KEY DEVELOPMENTS 58
9.3.5 KEY STRATEGIES 59
9.4 NOVARTIS AG 60
9.4.1 COMPANY OVERVIEW 60
9.4.2 FINANCIAL OVERVIEW 61
9.4.3 PRODUCTS OFFERED 61
9.4.4 KEY DEVELOPMENTS 61
9.4.5 SWOT ANALYSIS 62
9.4.6 KEY STRATEGIES 62
9.5 TAJ PHARMACEUTICALS LIMITED. 63
9.5.1 COMPANY OVERVIEW 63
9.5.2 FINANCIAL OVERVIEW 63
9.5.3 Products OFFERed 63
9.5.4 KEY DEVELOPMENTS 63
9.5.5 KEY STRATEGIES 64
9.6 CELON LABS 65
9.6.1 COMPANY OVERVIEW 65
9.6.2 FINANCIAL OVERVIEW 65
9.6.3 Products OFFERed 65
9.6.4 KEY DEVELOPMENTS 65
9.6.5 KEY STRATEGIES 65
9.7 SALIUS PHARMA PVT. LTD. 66
9.7.1 COMPANY OVERVIEW 66
9.7.2 FINANCIAL OVERVIEW 66
9.7.3 Products OFFERed 66
9.7.4 KEY DEVELOPMENTS 66
9.7.5 KEY STRATEGIES 66
9.8 PFIZER INC 67
9.8.1 COMPANY OVERVIEW 67
9.8.2 FINANCIAL OVERVIEW 68
9.8.3 productS OFFERED 68
9.8.4 KEY DEVELOPMENTS 69
9.8.5 SWOT ANALYSIS 69
9.8.6 KEY STRATEGIES 70
9.9 EMMAUS MEDICAL, INC 71
9.9.1 COMPANY OVERVIEW 71
9.9.2 FINANCIAL OVERVIEW 72
9.9.3 products OFFERED 72
9.9.4 KEY DEVELOPMENTS 72
9.9.5 SWOT ANALYSIS 73
9.9.6 KEY STRATEGIES 73
9.10 TEVA PHARMACEUTICAL INDUSTRIES LTD 74
9.10.1 COMPANY OVERVIEW 74
9.10.2 FINANCIAL OVERVIEW 75
9.10.3 productS OFFERED 75
9.10.4 KEY DEVELOPMENTS 75
9.10.5 SWOT ANALYSIS 76
9.10.6 KEY STRATEGIES 76
10 DATA CITATIONS 77
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 QFD MODELLING FOR MARKET SHARE ASSESSMENT 28
TABLE 2 INDIA SICKLE CELL ANAEMIA MARKET, BY TYPE, 2019–2032 (USD MILLION) 42
TABLE 3 INDIA SICKLE CELL ANAEMIA MARKET, BY DIAGNOSIS & TREATMENT, 2019–2032 (USD MILLION) 45
TABLE 4 INDIA SICKLE CELL ANAEMIA MARKET, BY TREATMENT, BY TYPE, 2019–2032 (USD MILLION) 45
TABLE 5 INDIA SICKLE CELL ANAEMIA MARKET, FOR PHARMACOTHERAPY, BY TYPE, 2019–2032 (USD MILLION) 46
TABLE 6 INDIA SICKLE CELL ANAEMIA MARKET, FOR DIAGNOISIS, BY TYPE, 2019–2032 (USD MILLION) 46
TABLE 7 INDIA SICKLE CELL ANAEMIA MARKET, FOR DIAGNOISIS, BY TYPE, 2019–2032 (UNITS) 46
TABLE 8 INDIA SICKLE CELL ANAEMIA MARKET, FOR INSTRUMENTS, BY TYPE, 2019–2032 (UNITS) 47
TABLE 9 INDIA SICKLE CELL ANAEMIA MARKET, FOR TEST KITS, BY TYPE, 2019–2032 (UNITS) 47
TABLE 10 PUBLIC PLAYERS STOCK SUMMARY 51
TABLE 11 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 51
TABLE 12 PRODUCT APPROVAL 52
TABLE 13 CIPLA LTD: PRODUCTS OFFERED 54
TABLE 14 UNITED BIOTECH PVT LTD: PRODCUTS OFFERED 56
TABLE 15 NEON: PRODUCTS OFFERED 58
TABLE 16 NOVARTIS AG: PRODUCTS OFFERED 61
TABLE 17 TAJ PHARMACEUTICALS LIMITED: PRODUCTS OFFERED 63
TABLE 18 CELON LABS: PRODUCTS OFFERED 65
TABLE 19 SALIUS PHARMA PVT. LTD.: PRODUCTS OFFERED 66
TABLE 20 PFIZER INC: PRODUCT OFFERED 68
TABLE 21 PFIZER INC: KEY DEVELOPMENTS 69
TABLE 22 EMMAUS MEDICAL, INC: PRODUCT OFFERED 72
TABLE 23 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERED 75
LIST OF FIGURES
FIGURE 1 INDIA SICKLE CELL ANEMIA MARKET: STRUCTURE 16
FIGURE 2 INDIA SICKLE CELL ANAEMIA MARKET REPORT: MARKET GROWTH FACTOR ANALYSIS (2022-2032) 32
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032) 34
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032) 35
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: INDIA SICKLE CELL ANAEMIA MARKET 37
FIGURE 6 INDIA SICKLE CELL ANAEMIA MARKET, TYPE SEGMENT ATTRACTIVENESS, 2022-2032 (USD MILLION) 41
FIGURE 7 INDIA SICKLE CELL ANAEMIA MARKET, BY TYPE, 2022 & 2032 (USD MILLION) 42
FIGURE 8 INDIA SICKLE CELL ANAEMIA MARKET SHARE (%), BY TYPE, 2022 43
FIGURE 9 INDIA SICKLE CELL ANAEMIA MARKET, DIAGNOSIS &TREATMENT SEGMENT ATTRACTIVENESS, 2022-2032 (USD MILLION) 44
FIGURE 10 INDIA SICKLE CELL ANAEMIA MARKET, BY DIAGNOSIS &TREATMENT, 2022 & 2032 (USD MILLION) 44
FIGURE 11 INDIA SICKLE CELL ANAEMIA MARKET SHARE (%), BY DIAGNOSIS & TREATMENT, 2022 45
FIGURE 12 INDIA SICKLE CELL ANAEMIA MARKET PLAYERS: COMPETITIVE ANALSIS, 2022 49
FIGURE 13 COMPETITOR DASHBOARD: INDIA SICKLE CELL ANAEMIA MARKET 50
FIGURE 14 CIPLA LTD: FINANCIAL OVERVIEW 54
FIGURE 15 CIPLA LTD: SWOT ANALYSIS 55
FIGURE 16 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 61
FIGURE 17 NOVARTIS AG: SWOT ANALYSIS 62
FIGURE 18 PFIZER INC: FINANCIAL OVERVIEW SNAPSHOT 68
FIGURE 19 PFIZER INC: SWOT ANALYSIS 69
FIGURE 20 EMMAUS MEDICAL, INC.: FINANCIAL OVERVIEW SNAPSHOT 72
FIGURE 21 EMMAUS MEDICAL, INC: SWOT ANALYSIS 73
FIGURE 22 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT 75
FIGURE 23 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS 76
提及公司
Cipla IncNovartis AGUnited Biotech Pvt ltd.Pfizer IncEmmaus MedicalIncNeonCelon Labsand Teva Pharmaceutical Industries Ltd.
同分類最新報告（醫療與生命科學）
查看醫療與生命科學全部報告 →
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們